Both TGFβ and lysyl oxidases can be targeted to improve response to radiotherapy: inhibition of TGFβ signaling enhances radiation sensitivity of non-small-cell lung cancer (NSCLC) cells in vitro and in a Lewis lung carcinoma mouse model (Kirshner et al., 2006; Du et al., 2015; Zhao et al., 2016). This evidence concerns the gene TGFB1 and non-small cell lung carcinoma.